Literature DB >> 30149917

p21-activated kinase 4 as a switch between caspase-8 apoptosis and NF-κB survival signals in response to TNF-α in hepatocarcinoma cells.

Qing Li1, Xiaoyun Zhang2, Na Wei1, Shuwen Liu3, Yaqin Ling4, Hao Wang5.   

Abstract

PAK4 is overexpressed in a variety of human cancers and considered a promising candidate for therapeutic target. However, its functions remain poorly understood, especially in liver carcinogenesis which could be triggered by inflammation. In the present study, endogenous PAK4 was knockdown using siRNA in HepG2 and SK-Hep1 cells. The two cell lines performed reduced cell viability, altered cell cycle composed of decreased S and arrest in G2, and apoptosis. Meanwhile, expression of NF-κB p65 in the nuclei and caspase-8 activity did not show significant differences from control. However, after treating cells with TNF-α, an inflammatory cytokine, we investigated repressed nuclear expression and localization of NF-κB p65, and induced apoptosis with increased caspase-8 activity in PAK4-knockdown cells. The findings revealed that ablation of PAK4 inhibited cell viability via blocking cell cycle and progressing apoptosis. The apoptosis was partially dependent upon caspase-8 concomitant with attenuated NF-κB survival signal due to stimulus of TNF-α. It suggests that PAK4 as target is a switch between caspase-8 apoptosis and NF-κB survival signals induced by TNF-α in hepatocarcinoma cells.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatocarcinoma; Inflammation; NF-κB; TNF-α; p21-activated kinase 4

Mesh:

Substances:

Year:  2018        PMID: 30149917     DOI: 10.1016/j.bbrc.2018.08.085

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Targeting p21-activated kinase 4 (PAK4) with pyrazolo[3,4-d]pyrimidine derivative SPA7012 attenuates hepatic ischaemia-reperfusion injury in mice.

Authors:  Yuancheng Mao; Eun Lee; Xiaohui Yang; Eun Ju Bae; Raok Jeon; Byung-Hyun Park
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

2.  PAK4 inhibition improves PD-1 blockade immunotherapy.

Authors:  Catherine S Grasso; Antoni Ribas; Gabriel Abril-Rodriguez; Davis Y Torrejon; Wei Liu; Jesse M Zaretsky; Theodore S Nowicki; Jennifer Tsoi; Cristina Puig-Saus; Ignacio Baselga-Carretero; Egmidio Medina; Michael J Quist; Alejandro J Garcia; William Senapedis; Erkan Baloglu; Anusha Kalbasi; Gardenia Cheung-Lau; Beata Berent-Maoz; Begoña Comin-Anduix; Siwen Hu-Lieskovan; Cun-Yu Wang
Journal:  Nat Cancer       Date:  2019-12-09

3.  PAK4 suppresses TNF-induced release of endothelial microparticles in HUVECs cells.

Authors:  Shouqin Zhang; Yingjie Yin; Congye Li; Yi Zhao; Qixing Wang; Xiangyu Zhang
Journal:  Aging (Albany NY)       Date:  2020-07-12       Impact factor: 5.682

4.  miR-185-5p Regulates Inflammation and Phagocytosis through CDC42/JNK Pathway in Macrophages.

Authors:  Xirui Ma; Huifang Liu; Jing Zhu; Caoxu Zhang; Yajie Peng; Ziming Mao; Yu Jing; Fengling Chen
Journal:  Genes (Basel)       Date:  2022-03-07       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.